Exenatide

Exenatide is a synthetic 39-amino acid peptide that is the pharmacological form of exendin-4, a naturally occurring peptide originally isolated from the saliva of the Gila monster lizard (Heloderma suspectum). Exendin-4 was discovered by John Eng at the Veterans Affairs Medical Center in New York in 1992, and its development into a therapeutic agent by Amylin Pharmaceuticals (later acquired by AstraZeneca) represented a landmark in diabetes pharmacotherapy as the first incretin mimetic approved by the FDA (2005).

Exenatide shares approximately 53% amino acid sequence homology with human GLP-1 but is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly inactivates native GLP-1. This resistance gives exenatide a half-life of approximately 2.4 hours, compared to 2 minutes for endogenous GLP-1. Exenatide activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon, slowing gastric emptying, and reducing appetite and food intake.

The original twice-daily injectable formulation (Byetta) was followed by the development of an extended-release formulation (Bydureon) that encapsulates exenatide in biodegradable polymer microspheres, allowing once-weekly dosing. Both formulations have demonstrated significant improvements in glycemic control (HbA1c reductions of 0.8-1.5%) and modest weight loss (2-4 kg) in patients with type 2 diabetes.

While exenatide paved the way for the incretin therapy revolution, it has been largely overshadowed commercially by longer-acting and more potent GLP-1 receptor agonists, particularly semaglutide and liraglutide. Nevertheless, exenatide maintains an important place in diabetes pharmacotherapy history and continues to be used in clinical practice, particularly the once-weekly Bydureon formulation.